

REFERENCES:

- R2: *Genomics Analysis and Visualization Platform* [Online]. Available: (<http://r2.amc.nl>) [Accessed].
- AHMED, A. A., ZHANG, L., REDDIVALLA, N. & HETHERINGTON, M. 2017. Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors. *Pediatr Hematol Oncol*, 34, 165-185.
- ALARCON, C. R., LEE, H., GOODARZI, H., HALBERG, N. & TAVAZOIE, S. F. 2015. N6-methyladenosine marks primary microRNAs for processing. *Nature*, 519, 482-5.
- ATCC. 2019a. *SH-SY5Y (ATCC® CRL-2266™)* [Online]. Available: <https://www.atcc.org/products/all/CRL-2266.aspx> [Accessed].
- ATCC. 2019b. *SK-N-AS (ATCC® CRL-2137™)* [Online]. Available: <https://www.atcc.org/products/all/CRL-2137.aspx#history> [Accessed].
- ATCC. 2019c. *SK-N-BE(2) (ATCC® CRL-2271™)* [Online]. Available: <https://www.atcc.org/Products/All/CRL-2271.aspx#generalinformation> [Accessed].
- BAGATELL, R., LONDON, W. B., WAGNER, L. M., VOSS, S. D., STEWART, C. F., MARIS, J. M., KRETSCHMAR, C. & COHN, S. L. 2011. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. *J Clin Oncol*, 29, 208-13.
- BARTEL, D. P. 2009. MicroRNAs: target recognition and regulatory functions. *Cell*, 136, 215-33.
- BOYERINAS, B., PARK, S. M., MURMANN, A. E., GWIN, K., MONTAG, A. G., ZILLHARDT, M., HUA, Y. J., LENGUEL, E. & PETER, M. E. 2012. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. *Int J Cancer*, 130, 1787-97.
- BRODEUR, G. M. 2003. Neuroblastoma: biological insights into a clinical enigma. *Nat Rev Cancer*, 3, 203-16.
- BUSSING, I., SLACK, F. J. & GROSSHANS, H. 2008. let-7 microRNAs in development, stem cells and cancer. *Trends Mol Med*, 14, 400-9.
- CASTILLO, J. J., TREON, S. P. & DAVIDS, M. S. 2016. Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. *Cancer J*, 22, 34-9.
- CHAKRABARTI, L., ABOU-ANTOUN, T., VUKMANOVIC, S. & SANDLER, A. D. 2012. Reversible adaptive plasticity: a mechanism for neuroblastoma cell heterogeneity and chemo-resistance. *Front Oncol*, 2, 82.
- CHEN, Y. & STALLINGS, R. L. 2007. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. *Cancer Res*, 67, 976-83.
- CHEN, Y., TAKITA, J., CHOI, Y. L., KATO, M., OHIRA, M., SANADA, M., WANG, L., SODA, M., KIKUCHI, A., IGARASHI, T., NAKAGAWARA, A., HAYASHI, Y., MANO, H. & OGAWA, S. 2008. Oncogenic mutations of ALK kinase in neuroblastoma. *Nature*, 455, 971-4.
- CHHABRA, R. 2018. let-7i-5p, miR-181a-2-3p and EGF/PI3K/SOX2 axis coordinate to maintain cancer stem cell population in cervical cancer. *Sci Rep*, 8, 7840.
- COOK, M. N., OLSHAN, A. F., GUESS, H. A., SAVITZ, D. A., POOLE, C., BLATT, J., BONDY, M. L. & POLLOCK, B. H. 2004. Maternal medication use and neuroblastoma in offspring. *Am J Epidemiol*, 159, 721-31.



- DAVIS, B. N., HILYARD, A. C., LAGNA, G. & HATA, A. 2008. SMAD proteins control DROSHA-mediated microRNA maturation. *Nature*, 454, 56-61.
- DE PRETER K, S. F., VANDESOMPELE J, MESTDAGH P, SERMON K, NOGUERA R, EGGERT A, SCHRAMM A, SCHULTE J 2018. Real-time quantitative PCR miRNA expression data of normal foetal adrenal neuroblasts and cortex cells, neuroblastoma tumors and embryonic stem cells. *GEO accession: GSE121513*.
- DEMETRI, G. D., TITTON, R. L., RYAN, D. P. & FLETCHER, C. D. 2004. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass. *N Engl J Med*, 351, 1779-87.
- DICK, J. E. 2003. Breast cancer stem cells revealed. *Proc Natl Acad Sci U S A*, 100, 3547-9.
- ELSABA, T. M., MARTINEZ-POMARES, L., ROBINS, A. R., CROOK, S., SETH, R., JACKSON, D., MCCART, A., SILVER, A. R., TOMLINSON, I. P. & ILYAS, M. 2010. The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer. *PLoS One*, 5, e10714.
- ESQUELA-KERSCHER, A., TRANG, P., WIGGINS, J. F., PATRAWALA, L., CHENG, A., FORD, L., WEIDHAAS, J. B., BROWN, D., BADER, A. G. & SLACK, F. J. 2008. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. *Cell Cycle*, 7, 759-64.
- FABBRI, M., PAONE, A., CALORE, F., GALLI, R., GAUDIO, E., SANTHANAM, R., LOVAT, F., FADDA, P., MAO, C., NUOVO, G. J., ZANESI, N., CRAWFORD, M., OZER, G. H., WERNICKE, D., ALDER, H., CALIGIURI, M. A., NANA-SINKAM, P., PERROTTI, D. & CROCE, C. M. 2012. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. *Proc Natl Acad Sci U S A*, 109, E2110-6.
- FABER, A., BARTH, C., HORMANN, K., KASSNER, S., SCHULTZ, J. D., SOMMER, U., STERN-STRAETER, J., THORN, C. & GOESSLER, U. R. 2011. CD44 as a stem cell marker in head and neck squamous cell carcinoma. *Oncol Rep*, 26, 321-6.
- FONTANA, L., FIORI, M. E., ALBINI, S., CIFALDI, L., GIOVINAZZI, S., FORLONI, M., BOLDRINI, R., DONFRANCESCO, A., FEDERICI, V., GIACOMINI, P., PESCHLE, C. & FRUCI, D. 2008. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. *PLoS One*, 3, e2236.
- FUKUDA, T., YAMAGATA, K., FUJIYAMA, S., MATSUMOTO, T., KOSHIDA, I., YOSHIMURA, K., MIHARA, M., NAITOU, M., ENDOH, H., NAKAMURA, T., AKIMOTO, C., YAMAMOTO, Y., KATAGIRI, T., FOULDS, C., TAKEZAWA, S., KITAGAWA, H., TAKEYAMA, K., O'MALLEY, B. W. & KATO, S. 2007. DEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAs. *Nat Cell Biol*, 9, 604-11.
- GE, Y., WANG, C., SONG, S., HUANG, J., LIU, Z., LI, Y., MENG, Q., ZHANG, J., YAO, J., LIU, K., MA, X. & SUN, X. 2018. Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. *Eur J Med Chem*, 143, 1847-1857.
- GEORGE, R. E., SANDA, T., HANNA, M., FROHLING, S., LUTHER, W., 2ND, ZHANG, J., AHN, Y., ZHOU, W., LONDON, W. B., MCGRADY, P., XUE, L., ZOZULYA, S., GREGOR, V. E., WEBB, T. R., GRAY, N. S., GILLILAND, D. G., DILLER, L., GREULICH, H., MORRIS, S. W., MEYERSON, M. & LOOK, A. T. 2008. Activating mutations in ALK provide a therapeutic target in neuroblastoma. *Nature*, 455, 975-8.
- GHEEYA, J. S., CHEN, Q. R., BENJAMIN, C. D., CHEUK, A. T., TSANG, P., CHUNG, J. Y.,

- METAFERIA, B. B., BADGETT, T. C., JOHANSSON, P., WEI, J. S., HEWITT, S. M. & KHAN, J. 2009. Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. *Cancer Biol Ther*, 8, 2386-95.
- GOEL, A. & AGGARWAL, B. B. 2010. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. *Nutr Cancer*, 62, 919-30.
- GUNDERSON, A. J., KANEDA, M. M., TSUJIKAWA, T., NGUYEN, A. V., AFFARA, N. I., RUFFELL, B., GORJESTANI, S., LIUDAH, S. M., TRUITT, M., OLSON, P., KIM, G., HANAHAN, D., TEMPERO, M. A., SHEPPARD, B., IRVING, B., CHANG, B. Y., VARNER, J. A. & COUSSENS, L. M. 2016. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. *Cancer Discov*, 6, 270-85.
- GUO, W., LIU, R., BHARDWAJ, G., YANG, J. C., CHANGOU, C., MA, A. H., MAZLOOM, A., CHINTAPALLI, S., XIAO, K., XIAO, W., KUMARESAN, P., SANCHEZ, E., YEH, C. T., EVANS, C. P., PATTERSON, R., LAM, K. S. & KUNG, H. J. 2014. Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. *Cell Death Dis*, 5, e1409.
- HALL, J., GUO, G., WRAY, J., EYRES, I., NICHOLS, J., GROTEWOLD, L., MORFOPOULOU, S., HUMPHREYS, P., MANSFIELD, W., WALKER, R., TOMLINSON, S. & SMITH, A. 2009. Oct4 and LIF/Stat3 additively induce Kruppel factors to sustain embryonic stem cell self-renewal. *Cell Stem Cell*, 5, 597-609.
- HANAHAN, D. & WEINBERG, R. A. 2011. Hallmarks of cancer: the next generation. *Cell*, 144, 646-74.
- HAWKINS, K., MOHAMED, L., RITSON, S., MERRY, C. L. & WARD, C. M. 2012. E-cadherin and, in its absence, N-cadherin promotes Nanog expression in mouse embryonic stem cells via STAT3 phosphorylation. *Stem Cells*, 30, 1842-51.
- HE, S., CHU, J., WU, L. C., MAO, H., PENG, Y., ALVAREZ-BRECKENRIDGE, C. A., HUGHES, T., WEI, M., ZHANG, J., YUAN, S., SANDHU, S., VASU, S., BENSON, D. M., JR., HOFMEISTER, C. C., HE, X., GHOSH, K., DEVINE, S. M., CALIGIURI, M. A. & YU, J. 2013. MicroRNAs activate natural killer cells through Toll-like receptor signaling. *Blood*, 121, 4663-71.
- HECK, J. E., RITZ, B., HUNG, R. J., HASHIBE, M. & BOFFETTA, P. 2009. The epidemiology of neuroblastoma: a review. *Paediatr Perinat Epidemiol*, 23, 125-43.
- HENDRIKS, R. W., YUVARAJ, S. & KIL, L. P. 2014. Targeting Bruton's tyrosine kinase in B cell malignancies. *Nat Rev Cancer*, 14, 219-32.
- HENNCHEN, M., STUBBUSCH, J., ABARCHAN-EL MAKHFI, I., KRAMER, M., DELLER, T., PIERRE-EUGENE, C., JANOUÉIX-LEROSEY, I., DELATTRE, O., ERNSBERGER, U., SCHULTE, J. B. & ROHRER, H. 2015. Lin28B and Let-7 in the Control of Sympathetic Neurogenesis and Neuroblastoma Development. *J Neurosci*, 35, 16531-44.
- HO, W. L., CHOU, C. H., JENG, Y. M., LU, M. Y., YANG, Y. L., JOU, S. T., LIN, D. T., CHANG, H. H., LIN, K. H., HSU, W. M. & HUANG, M. C. 2014. GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma. *Oncotarget*, 5, 12247-59.
- HOFMANN, J., DOPPLER, W., JAKOB, A., MALY, K., POSCH, L., UBERALL, F. & GRUNICKE, H. H. 1988. Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. *Int J Cancer*, 42, 382-8.
- HOUGHTON, P. J., MORTON, C. L., GORLICK, R., LOCK, R. B., CAROL, H., REYNOLDS,

- C. P., KANG, M. H., MARIS, J. M., KEIR, S. T., KOLB, E. A., WU, J., WOZNIAK, A. W., BILLUPS, C. A., RUBINSTEIN, L. & SMITH, M. A. 2010. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. *Mol Cancer Ther*, 9, 101-12.
- HSU, W. M., CHE, M. I., LIAO, Y. F., CHANG, H. H., CHEN, C. H., HUANG, Y. M., JENG, Y. M., HUANG, J., QUON, M. J., LEE, H., HUANG, H. C. & HUANG, M. C. 2011. B4GALNT3 expression predicts a favorable prognosis and suppresses cell migration and invasion via beta(1) integrin signaling in neuroblastoma. *Am J Pathol*, 179, 1394-404.
- HU, Y. P., WU, Z. B., JIANG, L., JIN, Y. P., LI, H. F., ZHANG, Y. J., MA, Q., YE, Y. Y., WANG, Z., LIU, Y. C., CHEN, H. Z. & LIU, Y. B. 2018. STYK1 promotes cancer cell proliferation and malignant transformation by activating PI3K-AKT pathway in gallbladder carcinoma. *Int J Biochem Cell Biol*, 97, 16-27.
- IMMERVOLL, H., HOEM, D., SAKARIASSEN, P. O., STEFFENSEN, O. J. & MOLVEN, A. 2008. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. *BMC Cancer*, 8, 48.
- IRWIN, M. S. & PARK, J. R. 2015. Neuroblastoma: paradigm for precision medicine. *Pediatr Clin North Am*, 62, 225-56.
- ITO, M., SHICHITA, T., OKADA, M., KOMINE, R., NOGUCHI, Y., YOSHIMURA, A. & MORITA, R. 2015. Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. *Nat Commun*, 6, 7360.
- IZUTSU, K. 2017. Treatment for mantle cell lymphoma. *Rinsho Ketsueki*, 58, 2026-2032.
- JANOUEIX-LEROSEY, I., LEQUIN, D., BRUGIERES, L., RIBEIRO, A., DE PONTUAL, L., COMBARET, V., RAYNAL, V., PUISIEUX, A., SCHLEIERMACHER, G., PIERRON, G., VALTEAU-COUANET, D., FREBOURG, T., MICHON, J., LYONNET, S., AMIEL, J. & DELATTRE, O. 2008. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. *Nature*, 455, 967-70.
- JOSHI, V. V., SILVERMAN, J. F., ALTSHULER, G., CANTOR, A. B., LARKIN, E. W., NEILL, J. S., NORRIS, H. T., SHUSTER, J. J., HOLBROOK, C. T., HAYES, F. A. & ET AL. 1993. Systematization of primary histopathologic and fine-needle aspiration cytologic features and description of unusual histopathologic features of neuroblastic tumors: a report from the Pediatric Oncology Group. *Hum Pathol*, 24, 493-504.
- KANIA, G., CORBEIL, D., FUCHS, J., TARASOV, K. V., BLYSZCZUK, P., HUTTNER, W. B., BOHELER, K. R. & WOBUS, A. M. 2005. Somatic stem cell marker prominin-1/CD133 is expressed in embryonic stem cell-derived progenitors. *Stem Cells*, 23, 791-804.
- KONDO, K., SHAIM, H., THOMPSON, P. A., BURGER, J. A., KEATING, M., ESTROV, Z., HARRIS, D., KIM, E., FERRAJOLI, A., DAHER, M., BASAR, R., MUFTUOGLU, M., IMAHASHI, N., ALSULIMAN, A., SOBIESKI, C., GOKDEMIR, E., WIERDA, W., JAIN, N., LIU, E., SHPALL, E. J. & REZVANI, K. 2017. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. *Leukemia*.
- LEE, C. S., RATTU, M. A. & KIM, S. S. 2016. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib. *J Oncol Pharm Pract*, 22, 92-104.
- LEE, R. C. & AMBROS, V. 2001. An extensive class of small RNAs in *Caenorhabditis elegans*. *Science*, 294, 862-4.
- LEE, R. C., FEINBAUM, R. L. & AMBROS, V. 1993. The *C. elegans* heterochronic gene *lin-4*

- encodes small RNAs with antisense complementarity to lin-14. *Cell*, 75, 843-54.
- LEE, Y. S. & DUTTA, A. 2009. MicroRNAs in cancer. *Annu Rev Pathol*, 4, 199-227.
- LESTARI, P., QORIANAS, N., TANJUNG, D. S., FITRIA, M. S., KARTIKA, A. I., WARDANA, T., RATNASARI, N., HARJANA, S. M. & ARYANDONO, T. 2016. *miR-21, miR-29c, and miR-155 as Biomarker to Develop Minimal Invasive Diagnostic in Hepatocellular Carcinoma Patient*.
- LIU, K., QIAN, T., TANG, L., WANG, J., YANG, H. & REN, J. 2012. Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. *World J Surg Oncol*, 10, 225.
- LIU, K., ZHANG, C., LI, T., DING, Y., TU, T., ZHOU, F., QI, W., CHEN, H. & SUN, X. 2015. Let-7a inhibits growth and migration of breast cancer cells by targeting HMGA1. *Int J Oncol*, 46, 2526-34.
- MANIKANDAN, J., AARTHI, J. J., KUMAR, S. D. & PUSHPARAJ, P. N. 2008. Oncomirs: the potential role of non-coding microRNAs in understanding cancer. *Bioinformation*, 2, 330-4.
- MATTHAY, K. K., MARIS, J. M., SCHLEIERMACHER, G., NAKAGAWARA, A., MACKALL, C. L., DILLER, L. & WEISS, W. A. 2016. Neuroblastoma. *Nat Rev Dis Primers*, 2, 16078.
- MCDERMOTT, S., SALZBERG, D. C., ANDERSON, A. P., SHAW, T. & LEAD, J. 2015. Systematic Review of Chromium and Nickel Exposure During Pregnancy and Impact on Child Outcomes. *J Toxicol Environ Health A*, 78, 1348-68.
- MENAA, F., HOUBEN, R., EYRICH, M., BROECKER, E. B., BECKER, J. C. & WISCHHUSEN, J. 2009. Stem cells, melanoma and cancer stem cells: the good, the bad and the evil? *G Ital Dermatol Venereol*, 144, 287-96.
- MESTDAGH, P., FREDLUND, E., PATTYN, F., SCHULTE, J. H., MUTH, D., VERMEULEN, J., KUMPS, C., SCHLIERF, S., DE PRETER, K., VAN ROY, N., NOGUERA, R., LAUREYS, G., SCHRAMM, A., EGGERT, A., WESTERMANN, F., SPELEMAN, F. & VANDESOMPELE, J. 2010. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. *Oncogene*, 29, 1394-404.
- MOHAMED, A. J., YU, L., BACKESJO, C. M., VARGAS, L., FARYAL, R., AINTS, A., CHRISTENSSON, B., BERGLOF, A., VIHINEN, M., NORE, B. F. & SMITH, C. I. 2009. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. *Immunol Rev*, 228, 58-73.
- MOHANTY, S., HUANG, J. & BASU, A. 2005. Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin 1. *Clin Cancer Res*, 11, 6730-7.
- MOLENAAR, J. J., KOSTER, J., ZWIJNENBURG, D. A., VAN SLUIS, P., VALENTIJN, L. J., VAN DER PLOEG, I., HAMDI, M., VAN NES, J., WESTERMAN, B. A., VAN ARKEL, J., EBUS, M. E., HANEVELD, F., LAKEMAN, A., SCHILD, L., MOLENAAR, P., STROEKEN, P., VAN NOESEL, M. M., ORA, I., SANTO, E. E., CARON, H. N., WESTERHOUT, E. M. & VERSTEEG, R. 2012. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. *Nature*, 483, 589-93.
- MOLINA-CERRILLO, J., ALONSO-GORDOA, T., GAJATE, P. & GRANDE, E. 2017. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors. *Cancer Treat Rev*, 58, 41-50.



- MORENO-SMITH, M., LAKOMA, A., CHEN, Z., TAO, L., SCORSONE, K. A., SCHILD, L., AVILES-PADILLA, K., NIKZAD, R., ZHANG, Y., CHAKRABORTY, R., MOLENAAR, J. J., VASUDEVAN, S. A., SHEEHAN, V., KIM, E. S., PAUST, S., SHOHET, J. M. & BARBIERI, E. 2017. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. *Clin Cancer Res*, 23, 6629-6639.
- MOSSE, Y. P., LAUDENSLAGER, M., LONGO, L., COLE, K. A., WOOD, A., ATTIYEH, E. F., LAQUAGLIA, M. J., SENNETT, R., LYNCH, J. E., PERRI, P., LAUREYS, G., SPELEMAN, F., KIM, C., HOU, C., HAKONARSON, H., TORKAMANI, A., SCHORK, N. J., BRODEUR, G. M., TONINI, G. P., RAPPAPORT, E., DEVOTO, M. & MARIS, J. M. 2008. Identification of ALK as a major familial neuroblastoma predisposition gene. *Nature*, 455, 930-5.
- MOYO, T. K., WILSON, C. S., MOORE, D. J. & EISCHEN, C. M. 2017. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition. *Oncogene*, 36, 4653-4661.
- OHMS, S., LEE, S. H. & RANGASAMY, D. 2014. LINE-1 retrotransposons and let-7 miRNA: partners in the pathogenesis of cancer? *Front Genet*, 5, 338.
- PARK, H. Y., LEE, K. J., LEE, S. J. & YOON, M. Y. 2012. Screening of peptides bound to breast cancer stem cell specific surface marker CD44 by phage display. *Mol Biotechnol*, 51, 212-20.
- PARK, J. R., EGGERT, A. & CARON, H. 2010. Neuroblastoma: biology, prognosis, and treatment. *Hematol Oncol Clin North Am*, 24, 65-86.
- PENG, Y. & CROCE, C. M. 2016a. The role of MicroRNAs in human cancer. *Signal Transduct Target Ther*, 1, 15004.
- PENG, Y. & CROCE, C. M. 2016b. The role of MicroRNAs in human cancer. *Signal Transduction And Targeted Therapy*, 1, 15004.
- PING, L., DING, N., SHI, Y., FENG, L., LI, J., LIU, Y., LIN, Y., SHI, C., WANG, X., PAN, Z., SONG, Y. & ZHU, J. 2017. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. *Oncotarget*, 8, 39218-39229.
- PINTO, N. R., APPLEBAUM, M. A., VOLCHENBOUM, S. L., MATTHAY, K. K., LONDON, W. B., AMBROS, P. F., NAKAGAWARA, A., BERTHOLD, F., SCHLEIERMACHER, G., PARK, J. R., VALTEAU-COUANET, D., PEARSON, A. D. & COHN, S. L. 2015. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. *J Clin Oncol*, 33, 3008-17.
- PISKAREVA, O., HARVEY, H., NOLAN, J., CONLON, R., ALCOCK, L., BUCKLEY, P., DOWLING, P., HENRY, M., O'SULLIVAN, F., BRAY, I. & STALLINGS, R. L. 2015. The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro. *Cancer Lett*, 364, 142-55.
- PRASAD, R. & KATIYAR, S. K. 2016. Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs. *Adv Exp Med Biol*, 928, 245-265.
- QIN, H., WEI, G., SAKAMAKI, I., DONG, Z., CHENG, W. A., SMITH, D. L., WEN, F., SUN, H., KIM, K., CHA, S., BOVER, L., NEELAPU, S. S. & KWAK, L. W. 2018. Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies In Vivo. *Clin Cancer Res*, 24, 1114-1123.



- QIU, Y. & KUNG, H. J. 2000. Signaling network of the Btk family kinases. *Oncogene*, 19, 5651-61.
- QUARTIER, P., DEBRE, M., DE BLIC, J., DE SAUVERZAC, R., SAYEGH, N., JABADO, N., HADDAD, E., BLANCHE, S., CASANOVA, J. L., SMITH, C. I., LE DEIST, F., DE SAINT BASILE, G. & FISCHER, A. 1999. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. *J Pediatr*, 134, 589-96.
- REYA, T., MORRISON, S. J., CLARKE, M. F. & WEISSMAN, I. L. 2001. Stem cells, cancer, and cancer stem cells. *Nature*, 414, 105-11.
- SAGIV-BARFI, I., KOHRT, H. E., CZERWINSKI, D. K., NG, P. P., CHANG, B. Y. & LEVY, R. 2015. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. *Proc Natl Acad Sci U S A*, 112, E966-72.
- SARTELET, H., IMBRIGLIO, T., NYALENDO, C., HADDAD, E., ANNABI, B., DUVAL, M., FETNI, R., VICTOR, K., ALEXENDROV, L., SINNETT, D., FABRE, M. & VASSAL, G. 2012. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway. *Histopathology*, 60, 1144-55.
- SAVITRI, E., SAFITRI SAFRI, J., DJAMIN, R., QADAR PUNAGI, A., KADIR, A., MUBARIKA, S. & WARDANA, T. 2017. *Expression of Micro RNA-21 and 29c in Blood Plasma of Patients with Nasopharyngeal Carcinoma*.
- SCHNEIDER, C. A., RASBAND, W. S. & ELICEIRI, K. W. 2012. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods*, 9, 671-5.
- SHIMADA, H., AMBROS, I. M., DEHNER, L. P., HATA, J., JOSHI, V. V. & ROALD, B. 1999a. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. *Cancer*, 86, 349-63.
- SHIMADA, H., AMBROS, I. M., DEHNER, L. P., HATA, J., JOSHI, V. V., ROALD, B., STRAM, D. O., GERBING, R. B., LUKENS, J. N., MATTHAY, K. K. & CASTLEBERRY, R. P. 1999b. The International Neuroblastoma Pathology Classification (the Shimada system). *Cancer*, 86, 364-72.
- SINGH, S. P., PILLAI, S. Y., DE BRUIJN, M. J. W., STADHOUDERS, R., CORNETH, O. B. J., VAN DEN HAM, H. J., MUGGEN, A., VAN, I. W., SLINGER, E., KUIL, A., SPAARGAREN, M., KATER, A. P., LANGERAK, A. W. & HENDRIKS, R. W. 2017. Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling. *Oncotarget*, 8, 71981-71995.
- SMITH, M. A., ALTEKRUSE, S. F., ADAMSON, P. C., REAMAN, G. H. & SEIBEL, N. L. 2014. Declining childhood and adolescent cancer mortality. *Cancer*, 120, 2497-506.
- SMITH, M. R. 2015. Ibrutinib in B lymphoid malignancies. *Expert Opin Pharmacother*, 16, 1879-87.
- SUI, Y. P., JIAN, X. P., MA, L. I., XU, G. Z., LIAO, H. W., LIU, Y. P. & WEN, H. C. 2016. Prognostic value of cancer stem cell marker CD133 expression in esophageal carcinoma: A meta-analysis. *Mol Clin Oncol*, 4, 77-82.
- TANZER, A. & STADLER, P. F. 2004. Molecular evolution of a microRNA cluster. *J Mol Biol*, 339, 327-35.
- THOMPSON, P. A. & BURGER, J. A. 2018. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). *Expert Opin Investig Drugs*, 27, 31-42.
- TRABUCCHI, M., BRIATA, P., GARCIA-MAYORAL, M., HAASE, A. D., FILIPOWICZ, W.,

- RAMOS, A., GHERZI, R. & ROSENFELD, M. G. 2009. The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs. *Nature*, 459, 1010-4.
- TRIPATHI, S. K., CHEN, Z., LARJO, A., KANDURI, K., NOUSIAINEN, K., AIJO, T., RICANO-PONCE, I., HRDLICKOVA, B., TUOMELA, S., LAAJALA, E., SALO, V., KUMAR, V., WIJMENGA, C., LAHDESMÄKI, H. & LAHESMAA, R. 2017. Genome-wide Analysis of STAT3-Mediated Transcription during Early Human Th17 Cell Differentiation. *Cell Rep*, 19, 1888-1901.
- WANG, J. C. & DICK, J. E. 2005. Cancer stem cells: lessons from leukemia. *Trends Cell Biol*, 15, 494-501.
- WANG, W., DONG, L. P., ZHANG, N. & ZHAO, C. H. 2014. Role of cancer stem cell marker CD44 in gastric cancer: a meta-analysis. *Int J Clin Exp Med*, 7, 5059-66.
- WANG, X., WONG, J., SEVINSKY, C. J., KOKABEE, L., KHAN, F., SUN, Y. & CONKLIN, D. S. 2016. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells. *Mol Cancer Ther*, 15, 2198-208.
- WARDANA, T., HERAWATI, C., OKTRIANI, R., ANWAR, S. L., ASTUTI, I., ARYANDONO, T. & MUBARIKA, S. 2016. Over- and down-expression mir-29c and mir-21 after chemotherapy and radio-therapy in nasopharyngeal carcinomas and the down-regulating proteins encoding eipstein barr virus and c-Myc.
- WEI, L., SU, Y. K., LIN, C. M., CHAO, T. Y., HUANG, S. P., HUYNH, T. T., JAN, H. J., WHANG-PENG, J., CHIOU, J. F., WU, A. T. & HSIAO, M. 2016. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. *Oncotarget*.
- WELCH, C., CHEN, Y. & STALLINGS, R. L. 2007. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. *Oncogene*, 26, 5017-22.
- WHITTLE, S. B., SMITH, V., DOHERTY, E., ZHAO, S., MCCARTY, S. & ZAGE, P. E. 2017. Overview and recent advances in the treatment of neuroblastoma. *Expert Rev Anticancer Ther*, 17, 369-386.
- WU, J., ZHANG, M. & LIU, D. 2017. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. *Oncotarget*, 8, 7201-7207.
- XU, W., YANG, Z. & LU, N. 2015. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. *Cell Adh Migr*, 9, 317-24.
- YAMAMOTO, K., OHTA, S., ITO, E., HAYASHI, Y., ASAMI, T., MABUCHI, O., HIGASHIGAWA, M. & TANIMURA, M. 2002. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. *J Clin Oncol*, 20, 1209-14.
- YANG, C. H., WANG, H. L., LIN, Y. S., KUMAR, K. P., LIN, H. C., CHANG, C. J., LU, C. C., HUANG, T. T., MARTEL, J., OJCIUS, D. M., CHANG, Y. S., YOUNG, J. D. & LAI, H. C. 2014. Identification of CD24 as a cancer stem cell marker in human nasopharyngeal carcinoma. *PLoS One*, 9, e99412.
- YANG, E. J., YOON, J. H. & CHUNG, K. C. 2004. Bruton's tyrosine kinase phosphorylates cAMP-responsive element-binding protein at serine 133 during neuronal differentiation in immortalized hippocampal progenitor cells. *J Biol Chem*, 279, 1827-37.
- YANG, N., KAUR, S., VOLINIA, S., GRESHOCK, J., LASSUS, H., HASEGAWA, K., LIANG, S., LEMINEN, A., DENG, S., SMITH, L., JOHNSTONE, C. N., CHEN, X. M., LIU, C. G., HUANG, Q., KATSAROS, D., CALIN, G. A., WEBER, B. L., BUTZOW, R., CROCE, C. M., COUKOS, G. & ZHANG, L. 2008. MicroRNA microarray identifies

- Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. *Cancer Res*, 68, 10307-14.
- YANG, Y., SHI, J., GU, Z., SALAMA, M. E., DAS, S., WENDLANDT, E., XU, H., HUANG, J., TAO, Y., HAO, M., FRANQUI, R., LEVASSEUR, D., JANZ, S., TRICOT, G. & ZHAN, F. 2015. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. *Cancer Res*, 75, 594-604.
- YANO, T. 2017. Chronic lymphocytic leukemia: biology, disease progression, and current treatment strategies. *Rinsho Ketsueki*, 58, 1960-1972.
- ZHANG, M., LIU, F., JIA, H., ZHANG, Q., YIN, L., LIU, W., LI, H., YU, B. & WU, J. 2011. Inhibition of microRNA let-7i depresses maturation and functional state of dendritic cells in response to lipopolysaccharide stimulation via targeting suppressor of cytokine signaling 1. *J Immunol*, 187, 1674-83.
- ZHANG, P., ANDRIANAKOS, R., YANG, Y., LIU, C. & LU, W. 2010. Kruppel-like factor 4 (Klf4) prevents embryonic stem (ES) cell differentiation by regulating Nanog gene expression. *J Biol Chem*, 285, 9180-9.
- ZHANG, P., MA, Y., WANG, F., YANG, J., LIU, Z., PENG, J. & QIN, H. 2012. Comprehensive gene and microRNA expression profiling reveals the crucial role of hsa-let-7i and its target genes in colorectal cancer metastasis. *Mol Biol Rep*, 39, 1471-8.
- ZUCHA, M. A., WU, A. T., LEE, W. H., WANG, L. S., LIN, W. W., YUAN, C. C. & YEH, C. T. 2015. Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. *Oncotarget*, 6, 13255-68.